Welcome to the TriologieGroup

The InnovationTriologie have recently completed a hybrid training program—combining web-based and face-to-face learning—on the current ICH-GCP E6(R3) guideline at Staburo GmbH in Munich. This comprehensive initiative has successfully trained more than 80 participants, equipping them with the essential knowledge and practical insights to implement the new Good Clinical Practice (GCP) guideline in the daily routines. Link: Staburo At ICH E6 (R3) Training  | Data science, biostatistics, data transparency, bioinformatics and statistical programming

The feedback has been very positive:
Participants engaged deeply with the material, appreciated the interactive format, and highlighted the relevance of the content to their day-to-day work in clinical research. We, at InnovationTriologie, are highly motivated by the positive feedback and are already looking forward to offering the next round of training.

Get Ready for July 2025

As a reminder, the new ICH-GCP E6(R3) guideline will become mandatory in the EU starting 23 July 2025. This shift brings important updates in quality- and risk management, data governance, and trial oversight—making preparation not just beneficial but essential.

InnovationTriologie is here to support organizations and professionals in understanding and applying these new standards. Whether you're an individual seeking to stay ahead or a company aiming to upskill your teams—we're ready to help you make the transition confidently.

📩 Reach out to us to learn more about our ACTA Education training options at training(at)triologie.org

With the release of the new ICH/GCP guideline ICH E6(R3) on 06-Jan-2025, continuous risk management in clinical trials has moved further into the spotlight. In this context, the use of Artificial Intelligence (AI) opens up new opportunities to meet the growing regulatory demands.

Helge Bonaventura and Dr. Andreas Berk described practical AI use cases that can enhance efficiency and mitigate risks in clinical research in a paper, that was published in the PM/QM journal by DGPharMed and German Quality Management Association e.V. In the article “Application of Artificial Intelligence in Risk Management of Clinical Trials” both aspects are addressed, the potential and the challenges of these technologies within the regulatory framework of ICH E6(R3).

The content of this article, which was also presented at the annual congress of DGPharMed 2025, reflects our ongoing commitment to innovation in clinical research and our efforts to improve the quality and safety of clinical trials by using AI tools and methods.

Download the full article as a PDF here: t3://file?uid=136

In the latest issue of pharmind (3/2025), Dr. Andreas Berk and Dr. Matthias Klüglich explore the growing role of Artificial Intelligence (AI) in Clinical Development. The article highlights current applications such as AI-assisted report generation, optimization of inclusion criteria, and automated quality control processes.

Both authors provide a balanced perspective, acknowledging the transformative potential of AI while emphasizing the importance of critically assessing its limitations and ethical implications. As the technology evolves rapidly, Dr. Matthias Klüglich and Dr. Andreas Berk call for ongoing evaluation to ensure responsible and effective integration into Clinical Research.

The role of Artificial Intelligence in Clinical Development was the central focus of a prestigious event held at the German Museum of Technology in Berlin. Initiated and supported by EventTriologie, the event brought together leading experts from Pharma and Industry to generate innovative impulses in Clinical Development. 

Instead of admission fees, donations were collected. A donation check of EUR 5,000 was presented to the Sonnenhof Children's Hospice in Berlin. The management and employees of BusinessTriologie were not just guests at this event – part of the donation was made possible by the entire BusinessTriologie team.

InnovationTriologie is proud to take responsibility for a comprehensive training concept. In today's clinical development environment, knowledge management has become an increasingly important factor. We are pleased to be able to provide a meaningful support to our customer.

Participants from InnovationTriologie attended the EUCROF25 congress in Copenhagen. The congress was meticulously designed to address the multifaceted nature of clinical research, covering essential topics such as regulatory changes, clinical trial technologies, quality assurance, data management and patient-centric approaches. The exchange with counterparts at European level was very helpful and provided new impulses.

In its 14th year, the Triologie Group continues to prioritize customer satisfaction as its core value. Our collaboration thrives on a commitment to excellence and a shared passion for achieving mutual project goals,

all within the complex framework of cost constraints and regulatory requirements in drug development. The trust shown by repeat business in 2025 serves as a powerful motivator for our entire team.

In 2025, we will embrace the theme of "STAYING TOGETHER," our vision aligned with the strategic decisions made by our leadership.

Effective July 1st, the executive team of BusinessTriologie expands as the new Chief Operating Officer assumes his position, enhancing our leadership. We warmly welcome Robert Kindervater and wish him great success in his new position.

Effective July 1st, the executive team of InnovationTriologie expands as the new Chief Operating Officer assumes his position, enhancing our leadership. We warmly welcome Dr. Andreas Berk and wish him great success in his new position.

We were represented at this year's DGPharMed congress on April 18^th and 19^th, 2024, in Mainz with two of our own exhibition stands. Detailed explanations and insights into our wide range of services, successful consultations, and information about our training academy ACTA were eagerly sought after. We are very pleased with the numerous interested parties and positive feedback that we were able to record.

On March 21^st, 2024  an expert discussion by InnovationTriologie on the topic “AI in drug development” took place in Berlin. Three engaging keynote speeches shed light on the development and application possibilities of artificial intelligence from various perspectives. This was followed by a discussion round that promoted interdisciplinary exchange. The event provided valuable insights and highlighted the importance of this topic for science, business, and society. 

Supporting the Sonnenhof children's hospice in Berlin (Björn Schulz Stiftung (bjoern-schulz-stiftung.de) is a personal endeavor for all of us. Our donation helps to improving the lives of children with life-limiting illnesses and to support their families in difficult circumstances.

Auch im 12. Jahr des Bestehens der Triologie-Unternehmensgruppe steht die Kundenzufriedenheit an erster Stelle. Einsatz und Freude an gemeinsamen Projektzielen unter den Kostenzwängen und der Regelungsdichte in der Arzneimittelentwicklung zeichnen diese Zusammenarbeit aus. Neue Projekte in den Bereichen Quality Management, Project Coaching und Wissensmanagement für unsere Kunden sind Motivation und Ansporn zugleich.

Nachhaltigkeit ist ein äußerst wichtiges Thema und ein zentrales Anliegen der gesamten Triologie Unternehmensgruppe. Eine Vielzahl von Maßnahmen wurden bereits vor 12 Jahren auf ein belastbares Fundament gestellt. Von der Entscheidung für ein umweltfreundliches Home-Office-Modell bis hin zur E-Mobility-Strategie übernimmt das „Team in Orange“ soziale Verantwortung.

Die gesamte TriologieUnternehmensgruppe wünscht allen Geschäftspartnern und ihren Familien ein gesundes und erfolgreiches Jahr 2024.

…